Wedbush Maintains Outperform on Larimar Therapeutics, Lowers Price Target to $12
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Wedbush analyst Laura Chico maintains Larimar Therapeutics (NASDAQ:LRMR) with a Outperform and lowers the price target from $13 to $12.
Wedbush analyst Laura Chico maintains Larimar Therapeutics (NASDAQ:LRMR) with a Outperform and lowers the price target from $13 to $12.